Abstract 5840
Background
ROS1 fusions are found in 1% of lung cancer patients. EUCROSS is the first prospective European trial to evaluate crizotinib in this patient subset. Here we present an updated analysis of the progression-free survival (PFS), overall survival (OS) and molecular characteristics of progression.
Methods
Multi-centre, single arm phase II trial. Key eligibility criteria: ≥18 years of age, advanced/metastatic lung cancer, centrally confirmed ROS1-rearrangement. Treatment: 250 mg crizotinib BID. Key endpoints of this report: updated PFS (according to RECIST 1.1) and OS and molecular tumour characterization.
Results
Thirty patients were eligible for response evaluation (N = 30; intention-to-treat population, N = 34). Median follow-up was 44.9 months (95% CI, 39.6-47.4). At data-cut off 19 patients (63.3%) discontinued treatment due to progression or death. Investigator-assessed efficacy: ORR, 70% (95% CI, 51–85; 21/30); disease control rate, 90.0% (95% CI, 73.5-97.9; 27/30); median PFS, 19.4 months (95% CI, 10.1-31.2); 24-months-OS probability, 65.5% (95% CI, 48.3-82.9). Prevalence of co-occurring genetic aberrations by hybrid-capture sequencing was 61%. TP53 mutations were most frequent (28%; 5/18). PFS (p = 0.0219) and OS at 24 months (p = 0.015) were significantly shorter in TP53-mutant patients. Tissue or blood samples were collected in six patients at progression. In three (50%) samples, secondary mutations in ROS1 (i.e. p.G2032R (N = 2), p.L2026M (N = 1)) were detected. In one (17%), a PIK3CA mutation (p.E545K) was identified. In the other two patients (33%) aberrations of unknown significance were detected.
Conclusions
Updated PFS and OS results confirm the efficacy of crizotinib in ROS1-rearranged lung cancer patients. Patients with co-mutations in TP53 had significantly worse outcomes compared to TP53 wild-type patients. The most common mechanisms of resistance were mutations in ROS1. Next-generation ROS1 inhibitors or the multi-kinase inhibitor cabozantinib may be promising treatment options for these patients.
Clinical trial identification
NCT02183870.
Editorial acknowledgement
Legal entity responsible for the study
University Hospital of Cologne.
Funding
Pfizer.
Disclosure
S. Michels: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self): Boehringer Ingelheim; Research grant / Funding (institution): Janssen; Honoraria (self): Roche. B. Massuti Sureda: Honoraria (self): Merck Sharp Dome; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Roche; Honoraria (self): Pfizer. H. Schildhaus: Honoraria (self): ZytoVision; Honoraria (self): Pfizer; Honoraria (self), Research grant / Funding (institution): Roche; Honoraria (self), Research grant / Funding (institution): Novartis. M. Sebastian: Honoraria (self): Boehringer Ingelheim; Honoraria (self): Eli Lilly; Honoraria (self): Pfizer; Honoraria (self): Roche; Honoraria (self): Novartis; Honoraria (self): AstraZeneca; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Merck Sharp Dome; Honoraria (self): Takeda; Honoraria (self): Mediolanum; Honoraria (self): AbbVie; Honoraria (self): Celgene. E. Felip: Honoraria (self): AstraZeneca; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Celgene; Honoraria (self): Eli Lilly; Honoraria (self): Guardiant; Honoraria (self): Merck Sharp Dome; Honoraria (self): Merck KGa; Honoraria (self): Novartis. M. Reck: Honoraria (self): Boehringer Ingelheim; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): AstraZeneca; Honoraria (self): Abbot; Honoraria (self): Celgene; Honoraria (self): Merck Sharp Dome; Honoraria (self): Merck KGa; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): Roche. S. Merkelbach-Bruse: Honoraria (self): Pfizer; Honoraria (self): AstraZeneca; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Roche; Honoraria (self), Research grant / Funding (institution): Novartis. L. Nogova: Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self), Research grant / Funding (institution): Janssen; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Roche; Honoraria (self): Celgene. J. Wolf: Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self), Research grant / Funding (institution): Janssen; Honoraria (self): Boehringer Ingelheim; Honoraria (self): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self): Chugay; Honoraria (self): Ignyta; Honoraria (self): Eli Lilly; Honoraria (self): Merck Sharp Dome; Honoraria (self): Roche. All other authors have declared no conflicts of interest.
Resources from the same session
5638 - Incidence of Vascular Thromboembolism Events in Cancer Patients Receiving Immunotherapy: A Single Institution Experience.
Presenter: Laura Gutiérrez Sainz
Session: Poster Display session 1
Resources:
Abstract
5182 - High Incidence of Venous Thromboembolic Events (VTE) in Patients with Diffuse Large B-Cell Lymphoma.
Presenter: Alaa Abufara
Session: Poster Display session 1
Resources:
Abstract
1504 - Weight Loss over Time in Non-Small Cell Lung Cancer: Results from a Landmark Analysis of 800+ Prospectively-Treated Patients
Presenter: Jennifer Le-rademacher
Session: Poster Display session 1
Resources:
Abstract
3972 - The prognostic significance of preoperative nutritional status in resected pancreatic ductal adenocarcinoma (PDAC).
Presenter: Salvatore Paiella
Session: Poster Display session 1
Resources:
Abstract
2313 - Impact of Timing and Technique of Gastrostomy Placement on the Outcome of Patients (pts) with Head and Neck Cancer (HNC)
Presenter: M Julia Lostes Bardaji
Session: Poster Display session 1
Resources:
Abstract
5219 - Clinical & nutritional determinants of quality of life in patients with incurable cancer
Presenter: Louise Daly
Session: Poster Display session 1
Resources:
Abstract
4075 - Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer
Presenter: In Gyu Hwang
Session: Poster Display session 1
Resources:
Abstract
4159 - Impact of nutritional derangement on treatment outcome in advanced non-small-cell lung cancer (A-NSCLC) patients (pts).
Presenter: Ilaria Trestini
Session: Poster Display session 1
Resources:
Abstract
1210 - Sarcopenia and pretreatment anemia as prognostic factors for patients with localized muscle invasive bladder cancer treated by neoadjuvant chemotherapy and radical cystectomy
Presenter: Emilien Billon
Session: Poster Display session 1
Resources:
Abstract
2490 - Gender effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of anamorelin (ANAM) in healthy volunteers and cancer patients with cachexia
Presenter: Stein Kaasa
Session: Poster Display session 1
Resources:
Abstract